MILDRONATE EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH CHRONIC HEART FAILURE: DOUBLE BLIND CROSSOVER STUDY
https://doi.org/10.20996/1819-6446-2008-4-2-38-40
Abstract
Aim. To study effect of mildronate on stream-dependent vasodilation in patients with chronic heart failure (CHF).
Material and methods. 30 patients with CHF taking standard therapy (diuretic, ACE inhibitor, β- blocker) as well as 30 healthy volunteers have been examined. Test of reactive hyperemia (RH) of brachial artery (BA) was performed in all patients. RH test was performed in patients with CHF in double blind crossover manner before and after infusion of NaCl-isotonic solution (placebo) or mildronate 1000 mg in NaCl-isotonic solution.
Results. Increase in BA diameter (%∆D) in patients with CHF was less than this in control group (p<0,01) during RH test. After mildronate infusion increase in %∆D during RH phase was observed (from 8,6+0,8 to 14,4+0,9%, р><0,001). After placebo infusion BA diameter did not change significantly (from 9,3+0,7 to 10,4+0,8%, p>0,05).
Conclusion. Mildronate improves endothelium-dependent vasodilation in patients with stable CHF.
About the Authors
L. G. Voronkov
National scientific centre «Cardiology Institute named after academician N.D. Strazhesko», Мedical Sciences Academy of Ukraine, Kiev
Russian Federation
Russian Federation
A. A. I.Shkurat
National scientific centre «Cardiology Institute named after academician N.D. Strazhesko», Мedical Sciences Academy of Ukraine, Kiev
Russian Federation
Russian Federation
E. A. Lutsak
National scientific centre «Cardiology Institute named after academician N.D. Strazhesko», Мedical Sciences Academy of Ukraine, Kiev
Russian Federation
Russian Federation
References
1. Remzi Onder M., Baritcuoglu B. Endothelium. Milano: One Way Publ.; 2006.
2. Ferrari R., Bachetti T., Agnoletti L. et al. Endothelial function and dysfunction in heart failure. Europ Heart J 1998;19 (Suppl G): G41-G48.
3. Drexler H., Hornig B. Role of peripheral circulation and endothelial cell dysfunction. In.: Heart Failure. Ed.D.L. Mann. Philadelphia: Saunders; 2004. p.109-122.
4. Yoshimuzi M., Perella M.A., Burnett I.C. et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circul Res 1993;73(1):205-9.
5. Ikeda U., Kanbe T., Nakayama I. et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Europ J Pharmacol 1995;290(2):69-73.
6. Sawyer D.B., Colucci W.S. Oxidatie stress in Heart Failure. In Heart Failure. Ed. D.L. Mann. Philadelphia: Saunders; 2004. p.181-192.
7. Hornin B., Arakawa N., Kohler C. et al. Vitamin C improves endothelium function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363-8.
8. Katz S.D., Schwarz M., Yuen J. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88:55-61.
9. Celemajer D.M., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
10. Воронков Л.Г., Шкурат І.А., Бесага Є.М. Ендотелій-залежна вазодилатація та її прогностичне значення у хворих хронічною серцевою недостатністю та систолічною дисфункцією лівого щлуночка. Укр кардіол журнал 2005;(6):86-89.
11. Fischer D., Rossa S., Landmesser U. et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiotransplantation, or death. Europ Heart J 2005;26(1):65- 9.
12. Skarda J., Klincare D., Dzerve V. Modulation of myocardial energy metabolism with mildronate – an effective approach in the treatment of chronic heart failure. Proc Latv Acad Sci 2001;55:73-9.
13. Тепляков А.Т., Санкевич Т.В., Степачева Т.А., Мамчур С.Е. Миокардиальная цитопротекция ингибитором β-окис- ления жирных кислот милдронатом в виде монотерапии и в сочетании с β-адреноблокатором атенололом у больных с постинфартной дисфункцией левого желудочка. Кардиология 2002;(12):15-18.
14. Веверис М.М., Атаре З.А., Кименис А.А., Калвиньш И.Я. Результаты фармакологического исследования мил- дроната. Эксп клин фармакотер 1991;(19):15-22.
15. Dzintare M., Baumane L., Veirena D. et al. Involvement of nitric oxide production in the mildronate mechanism of action. Pharmacol Rev and Comm 2002;12,:163-70.
16. Шапошник И.И., Салашенко А.О. Еффективность лечения милдронатом больных с сочетанием ишемической болезни сердца и дисциркуляторной энцефалопатии. Медичні перспективи 2007;(3): 27-33.
17. Шабалин А.В., Рогино Ю.И., Любимцева С.А. и др. Влияние цитопротекции на окислительные процессы и эн- дотелиальную функцию у пожилых пациентов с ишемической болезнью сердца. Рационал фармакотер кардиол 2006;(3):32-36.
18. Калвиньш И.Я. Милдронат – механизм действия и перспективы его применения. Рига: ПАО «Гриндекс»; 2001.
19. Суслина З.А., Максимова М.Ю., Федорова Т.Н. Хронические цереброваскулярные заболевания: клиническая и антиоксидантная эффективность милдроната. Врач 2007;(4):40-4.
20. Gheorghiade M., Bonow R.O. Heart failure as a consequence of atherosclerotic coronary artery disease. In Heart Failure. Ed. D.L. Mann. Philadelphia: Saunders; 2004. p.351-352.
Review
For citations:
Voronkov L.G., I.Shkurat A.A., Lutsak E.A. MILDRONATE EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH CHRONIC HEART FAILURE: DOUBLE BLIND CROSSOVER STUDY. Rational Pharmacotherapy in Cardiology. 2008;4(2):38-40. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-2-38-40
Views:
796
Email this article 